Aidoc Secures $150M for Medical AI Diagnosis Expansion

Aidoc, a leading medical AI company, has secured $150 million in new funding. General Catalyst and Square Peg co-led the round. This investment brings Aidoc's total funding to $370 million.

NVentures, NVIDIA’s investment arm, joined as a new investor.

Several major U.S. health systems also participated. Approximately $40 million of the funding came through a revolving credit facility.

Advancing AI Diagnosis Capabilities

The capital will accelerate development of CARE, Aidoc’s new Foundation Model for AI diagnosis. This model underpins two recently FDA approvaled AI products. It adds to dozens of prior approvals, enhancing healthcare technology.

Aidoc's platform, a key player in medical AI, is installed in thousands of hospitals globally. Currently, it helps treat over 45 million patients annually. The company expects to double this figure to 100 million within three years.

The new technology significantly speeds algorithm development. It builds algorithms ten times faster than previous methods. This rapid pace allows for more comprehensive insights into patient conditions, pushing AI innovation.

Aidoc, founded in 2016, provides real-time clinical decision support. Its FDA-cleared products detect life-threatening conditions. These include brain hemorrhages, pulmonary embolisms, and strokes. Competitors in the medical AI space include Viz.ai and Qure.ai.